Drugs / Magnesium Citrate
Magnesium Citrate
Trials 6
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT04941703 | Nov 2021 → Jun 2022 | COVID-19 | Vanderbilt University Medical Center | Terminated | No outcome recorded Stop: Enrollment |
| Phase 22 trials | ||||||
| Phase 2 | NCT02837328 | Mar → Sep 2017 | cardiac rhythm disease | University of Minnesota | Completed | No outcome recorded |
| Phase 2 | NCT02979223 | Nov 2016 → Jun 2017 | — | National Cancer Center, Korea | Completed | No outcome recorded |
| Phase 32 trials · 1 missed | ||||||
| Phase 3 | NCT05018221 | Aug 2021 → Dec 2029 expected | calciphylaxis cutis | University of Sydney | Recruiting | No outcome recorded |
| Phase 3 | NCT02032186 | Mar 2014 → Aug 2015 | magnesium deficiency | Professor Fernando Figueira Integral Medicine Institute | Completed | Missed primary |
| Phase not applicable1 trial · 1 missed | ||||||
| — | NCT03632590 | Mar 2018 → Jan 2020 | arterial disorder | University Medical Center Groningen | Unknown | Missed primary |
| Comparator or background therapy9 trials | ||||||
| Phase 2 | NCT06321796 Background | Feb 2024 → Feb 2025 | Pitt-Hopkins syndrome | Gut-Brain-Axis Therapeutics Inc. | Unknown | No outcome recorded |
| Phase 2 | NCT04132427 Background | Sep 2019 → Mar 2022 | Pitt-Hopkins syndrome | Arizona State University | Completed | No outcome recorded |
| Phase 4 | NCT03698474 Comparator | Oct 2018 → Feb 2019 | — | Tomas Bata Hospital, Czech Republic | Completed | No outcome recorded |
| Phase 4 | NCT03088852 Comparator | May 2017 → Dec 2025 overdue | magnesium deficiency | Frieda Wolf | Recruiting | No outcome recorded |
| Phase 4 | NCT02977286 Background | Jan 2017 → Oct 2019 | constipation disorder | Tufts Medical Center | Terminated | No outcome recorded Stop: Enrollment |
| Phase 4 | NCT02956057 Comparator | Nov 2016 → May 2017 | — | Tomas Bata Hospital, Czech Republic | Completed | No outcome recorded |
| Phase 4 | NCT02024022 Comparator | Feb 2014 → Sep 2015 | — | Clinical Hospital Colentina | Completed | No outcome recorded |
| Phase 4 | NCT01649674 Comparator | Nov 2011 → Dec 2024 | — | National Cancer Institute, Naples | Unknown | No outcome recorded |
| — | NCT01596686 Comparator | May → Dec 2012 | — | Clinical Hospital Colentina | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 15 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Magnesium citrate | “comparing sodium picosulphate and magnesium citrate versus 4-liter split-dose polyethylene glycol (PEG)” PMID 23799210 ↗ Jun 201313“bowel cleansing with either 4L PEG or sodium picosulphate/magnesium citrate” NCT02024022 ↗ “400 mg Magnesium Citrate 1x daily for 12 weeks” NCT02837328 ↗ “Magnesium Citrate” NCT03632590 ↗ |
| Known as | Natrium picosulfate / Magnesium citrate | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03698474 ↗ |
| Known as | Picoprep | “Natrium picosulfate /Magnesium citrate ( Picoprep™, oral solution) 2L in the evening before colonoscopy” NCT03698474 ↗ |
| Route | Oral | “Oral Mg++citrate, 160 mg twice daily.” NCT02032186 ↗ |